BLASINGLE-USEVIALPriority Review
Approved
Jun 2012
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
PERJETA (pertuzumab) by Roche is her2/neu/cerbb2 antagonists [moa]. Approved for her2/neu receptor antagonist [epc]. First approved in 2012.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERJETA (pertuzumab) is a monoclonal antibody that antagonizes HER2/neu receptor signaling, used to treat HER2-positive cancers. It binds to a distinct epitope on HER2 compared to trastuzumab, blocking ligand-induced signaling and enabling synergistic anti-tumor activity when combined with other HER2-targeted agents. The drug is administered as an intravenous infusion and is typically used in combination regimens for breast cancer.
$11MPart D
PeakPERJETA is in peak commercial phase with stable Part D spending; the commercial team is mature and focused on maintaining market position against biosimilar and new mechanism competition.
Mechanism of Action
HER2/Neu/cerbB2 Antagonists
Pharmacologic Class:
HER2/neu Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Started May 2026
60 enrolled
HER2-positive Recurrent or Metastatic Breast Cancer
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Started Apr 2026
596 enrolled
HER2-positive Breast Cancer
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Started Nov 2025
63 enrolled
Biliary Tract Cancer (BTC)First-line Therapy
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Started Jun 2025
642 enrolled
Breast Cancer
Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer
Started Jun 2025
24 enrolled
Rectal CancerHER2-positive
Worked on PERJETA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.